Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

Phase 3 Completed 76 enrolled Talphera, Inc U.S. Army Medical Research and Development Command · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of sufentanil tablet (ST) 30 mcg in the management of moderate-to-severe acute pain in patients in an emergency room (ER) setting.

Timeline

Start: 2015-10
Primary completion: 2016-06
Completion: 2016-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sufentanil	Other / unclassified	30 ug	Other

Indications

No indication recorded.